A phase II trial of interleukin-2 and interferon Alfa-2a in patients with advanced renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

abstract

  • In view of the minimal antitumor activity and associated toxicity, the combination of IL-2 and IFN-alpha in this trial cannot be recommended. The investigation of new cytokines and the identification of biologic prognostic factors for a response to immunologic therapy are essential.

publication date

  • December 1992

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 1607918

Additional Document Info

start page

  • 1124

end page

  • 30

volume

  • 10

number

  • 7